Phase 1
Completed N=19
Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers
Healthy
Source: ClinicalTrials.gov NCT01119222 ↗
Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Mar 2011
Primary outcomePrimary: Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS) — 45.2; 45.5; 45.0; 44.9 mm
Summary
Human experimental pain models are useful in understanding the mechanisms underlying clinical pain conditions and can be used to test the analgesic efficacy of drugs used in the management of pain. Once established these models can be used as mechanism biomarkers in early development clinical studies to establish proof of mechanism for novel compounds. The cold pain model is a mechanistic pain biomarker with potential application in proof of mechanism studies. In this study we aim to set up this cold pain model at a Clinical Research Unit and demonstrate we can effectively screen subjects for this model and examine the effect of morphine, diphenhydramine, and gabapentin in the cold pain model.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS) |
45.2; 45.5; 45.0; 44.9; 41.9; 28.6 | — |
| PRIMARY Interpolated Average Pain (0-8 Hours) |
42.2; 33.4; 43.6; 42.8 | — |
| SECONDARY Number of Participants With Clinically Significant Findings in Vital Signs |
— | — |
| SECONDARY Number of Participants With Clinically Significant Abnormal Findings on Physical Examination |
— | — |
| SECONDARY Number of Participants With Abnormal Findings on Electrocardiogram (ECG) |
— | — |
| SECONDARY Number of Participants With Abnormal Haematology, Clinical Chemistry, Urinalysis Results |
— | — |
| SECONDARY Number of Participants With Abnormal Cardiac Monitoring Results |
— | — |
| SECONDARY Number of Participants With Abnormal Pulse Oxymetry Results |
— | — |
Eligibility Criteria
Inclusion Criteria
- Healthy male volunteers having given consent to participate in the study who have no clinically significant anomalies and whose vital signs are within normal range.
- Subject having performed the cold pain test reproducibly ie, if the area under the pain-time curve (AUC) must be within 20% during successive tests within one cold pain test screening visit and within 30% between the two cold pain test screening visits.
Exclusion Criteria
- Subject who have had a serious adverse reaction or significant hypersensitivity to any of the study drugs.
- Subjects with a history of or evidence of any neurological condition which could affect pain sensation.
- Subjects with an AUCcpt 0-120 sec in the cold pain test of <1000 in any of the screening tests (excluding familiarization).
Data sourced from ClinicalTrials.gov (NCT01119222). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.